Aarhus University Hospital's department of molecular medicine has selected CLC Bio to develop a bioinformatics platform to analyze both microarray and next-generation sequence data as part of a $4 million research project exploring molecular approaches to predicting prostate cancer risk and aggressiveness
The project, funded by the Danish Council for Strategic Research, will use CLC Bio's tools to identify and validate new molecular markers associated with prostate cancer aggressiveness. The project will rely on data generated by NGS technologies and microarrays, and will use samples from a prostate cancer tissue biobank with clinical annotation.
Identifying whether a tumor is aggressive is important for selecting the right treatment for the patient, Torben Orntoft, a professor of molecular medicine at Aarhus University Hospital, said in a statement.
Roald Forsberg, CLC Bio's director of research and development, described the project as "perfect fit" for the company because it falls within its "core focus to invent, design, and develop novel bioinformatics software ... [for] molecular diagnostics."
He also said that the platform CLC Bio is developing for the project will enable integrated analysis of copy number variation, loss of heterozygosity, methylation, mRNA, miRNA, ncRNA, and other cancer-related biomarkers.
Other partners involved in the project are researchers from Aarhus University's bioinformatics research center and its research unit for general medicine; the University of Southern California, the University of Erlangen-Nuremberg, and China's BGI.